[HTML][HTML] The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy
G Pavlasova, M Mraz - Haematologica, 2020 - ncbi.nlm.nih.gov
The introduction of anti-CD20 monoclonal antibodies such as rituximab, ofatumumab, or
obinutuzumab improved the therapy of B-cell malignancies even though the precise …
obinutuzumab improved the therapy of B-cell malignancies even though the precise …
[HTML][HTML] Therapeutic antibodies: what have we learnt from targeting CD20 and where are we going?
Therapeutic monoclonal antibodies (mAbs) have become one of the fastest growing classes
of drugs in recent years and are approved for the treatment of a wide range of indications …
of drugs in recent years and are approved for the treatment of a wide range of indications …
The mystery of chronic lymphocytic leukemia (CLL): Why is it absent in Asians and what does this tell us about etiology, pathogenesis and biology?
SM Yang, JY Li, RP Gale, XJ Huang - Blood reviews, 2015 - Elsevier
Chronic lymphocytic leukemia/small lymphocytic lymphoma is common in persons of
predominately European descent but rare in Asians. Why is unknown but is likely genetically …
predominately European descent but rare in Asians. Why is unknown but is likely genetically …
Overexpression of IL-9 induced by STAT3 phosphorylation is mediated by miR-155 and miR-21 in chronic lymphocytic leukemia
N Chen, L Feng, H Qu, K Lu, P Li, X Lv… - Oncology …, 2018 - spandidos-publications.com
Abstract Interleukin‑9 (IL‑9) can function as both a positive and negative regulator of immune
response, however the role of IL‑9 in tumor immunity is poorly understood. Chronic …
response, however the role of IL‑9 in tumor immunity is poorly understood. Chronic …
[HTML][HTML] Role of high expression of IL-9 in prognosis of CLL
N Chen, X Lv, P Li, K Lu, X Wang - International Journal of Clinical …, 2014 - ncbi.nlm.nih.gov
Chronic lymphocytic leukemia (CLL) is a common leukemia in adults, but its pathogenesis is
still poorly understood. Interleukin-9 (IL-9) is initially described as a growth factor secreted …
still poorly understood. Interleukin-9 (IL-9) is initially described as a growth factor secreted …
Targeted Silencing of NRF2 by rituximab-conjugated nanoparticles increases the sensitivity of chronic lymphoblastic leukemia cells to Cyclophosphamide
A Khodakarami, MA Kashani, A Nazer… - Cell Communication and …, 2023 - Springer
Background Targeting influential factors in resistance to chemotherapy is one way to
increase the effectiveness of chemotherapeutics. The nuclear factor erythroid 2-related …
increase the effectiveness of chemotherapeutics. The nuclear factor erythroid 2-related …
CD20 expression as a possible novel prognostic marker in CLL: application of EuroFlow Standardization technique and normalization procedures in flow cytometric …
A Schilhabel, PJ Walter, P Cramer, J von Tresckow… - Cancers, 2022 - mdpi.com
Simple Summary Up to 50% of patients with chronic lymphocytic leukemia relapse within
four years after anti-CD20-directed treatment with a need for a subsequent treatment, which …
four years after anti-CD20-directed treatment with a need for a subsequent treatment, which …
[HTML][HTML] Prognostic impact of Epstein-Barr virus (EBV)-DNA copy number at diagnosis in chronic lymphocytic leukemia
Abstract Epstein-Barr virus (EBV)-DNA is detected in the blood of some persons with chronic
lymphocytic leukemia (CLL) at diagnosis. Whether this is important in the development or …
lymphocytic leukemia (CLL) at diagnosis. Whether this is important in the development or …
Brain stereotactic biopsy flow cytometry for central nervous system lymphoma characterization: advantages and pitfalls
I Cordone, S Masi, M Carosi, A Vidiri… - Journal of Experimental …, 2016 - Springer
Background Brain stereotactic biopsy (SB) followed by conventional histopathology and
immunohistochemistry (IHC) is the gold standard approach for primary central nervous …
immunohistochemistry (IHC) is the gold standard approach for primary central nervous …
Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab
Infusion-related reactions (IRRs) elicited by therapeutic antibodies are commonly observed
in the treatment of hematologic malignancies. In contrast to the currently approved type 1 …
in the treatment of hematologic malignancies. In contrast to the currently approved type 1 …